ZURICH (Reuters)—Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult and pediatric Crohn’s disease, adult and pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis,…
One Step Closer to Personalized Medicine for RA Patients
New research is translating the molecular signals in RA patients to better understand the earliest signs of disease. The work on using these signs to test the effects of RA treatment may help rheumatologists determine the most effective treatment for individuals…
Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
NEW YORK (Reuters Health)—Children of women with rheumatoid arthritis (RA) who are exposed to tumor necrosis factor-alpha inhibitors (TNFis) in the womb are not at markedly increased risk of serious infections, new findings suggest. “It’s reassuring for mothers who need to take these medications during pregnancy,” Evelyne Vinet, MD, of McGill University Health Center in…
Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles
NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,…
Antiplatelet Therapy May Protect Renal Function in Some Lupus Patients
New research suggests that antiplatelet therapy may improve the estimated glomerular filtration rate in lupus anticoagulant-positive patients with lupus nephritis. Researchers found these patients had a higher eGFR level after three years than lupus anticoagulant-positive patients who did not receive antiplatelet therapy…
Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab
New research has linked alendronate to reduced cardiovascular death in hip fracture patients…
Researchers Compare Nonsurgical Knee OA Treatments
According to new research, knee OA patients reported greater pain relief from intra-articular corticosteroids, but naproxen was more effective at improving function…
Healthcare Providers Should Encourage Exercise for OA Patients
A systemic review supports the ideas that exercise benefits the physical and mental health of patients experiencing pain related to hip and/or knee osteoarthritis (OA). Overall, research indicates that patients who exercised had slightly lower rates of pain and greater physical function, as well as slightly improved self-efficacy and social function…
Avoid Errors: Insights into Ensuring Accurate Data in EHRs
With the increasing use of electronic health records and quality measure reporting requirements, data collection has become crucial for rheumatologists. But how do clinicians prevent human error and ensure data accuracy?
ACR/ARHP Members Call on Congress to Restore Patients’ Voices
WASHINGTON, D.C.—The ACR hosted the 2018 Advocacy Leadership Conference in Washington, D.C., on May 16–17. Rheumatology professionals from around the country flew to our nation’s capitol to attend the conference, where advocates heard from key policymakers and spoke with lawmakers about the issues that affect the rheumatology community—and what ACR/ARHP members can do to influence policy….
- « Previous Page
- 1
- …
- 340
- 341
- 342
- 343
- 344
- …
- 819
- Next Page »